QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
QQQ   386.20 (+0.80%)
AAPL   165.32 (+2.15%)
MSFT   326.19 (+0.98%)
FB   317.87 (+3.59%)
GOOGL   2,863.10 (+0.81%)
AMZN   3,427.37 (+1.11%)
TSLA   1,009.01 (-0.59%)
NVDA   300.37 (-2.14%)
BABA   123.60 (+10.40%)
NIO   32.34 (+0.59%)
CGC   10.15 (+1.60%)
AMD   139.06 (-3.44%)
GE   96.01 (+3.49%)
MU   82.45 (+1.02%)
T   23.28 (-0.77%)
F   19.22 (+0.42%)
DIS   150.37 (+2.84%)
PFE   51.48 (-5.14%)
AMC   28.79 (-0.76%)
ACB   5.97 (+2.58%)
BA   205.88 (+3.72%)
NASDAQ:ANIK

Anika Therapeutics Stock Forecast, Price & News

$39.25
+1.16 (+3.05%)
(As of 12/6/2021 12:00 AM ET)
Add
Compare
Today's Range
$38.12
$39.82
50-Day Range
$38.09
$45.03
52-Week Range
$32.30
$48.37
Volume
70,679 shs
Average Volume
101,377 shs
Market Capitalization
$566.65 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.16
30 days | 90 days | 365 days | Advanced Chart
Receive ANIK News and Ratings via Email

Sign-up to receive the latest news and ratings for Anika Therapeutics and its competitors with MarketBeat's FREE daily newsletter.


Anika Therapeutics logo

About Anika Therapeutics

Anika Therapeutics, Inc. is an orthopedic and regenerative medicines company, which develops, manufactures and commercializes therapeutic products for pain management, tissue regeneration, and wound healing. Its products are based on hyaluronic acid, a natural chemical occurring, biocompatible polymer found throughout the body. It offers therapeutic products which include orthobiologics, dermal, ophthalmic, surgical, ophthalmic and veterinary. The company was founded in 1992 and is headquartered in Bedford, MA.

Headlines

Anika Therapeutics, Inc. (NASDAQ:ANIK) Short Interest Update
December 2, 2021 |  americanbankingnews.com
Anika Therapeutics earnings preview: what Wall Street is expecting
November 5, 2021 |  markets.businessinsider.com
Anika Reports Third Quarter 2021 Financial Results
November 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical & medical instruments
Sub-Industry
Health Care Supplies
Sector
Medical
Current Symbol
NASDAQ:ANIK
CUSIP
03525510
Employees
277
Year Founded
1992

Sales & Book Value

Annual Sales
$130.46 million
Cash Flow
$5.54 per share
Book Value
$20.09 per share

Profitability

Net Income
$-23.98 million
Pretax Margin
-4.52%

Debt

Price-To-Earnings

Miscellaneous

Free Float
14,280,000
Market Cap
$566.65 million
Optionable
Optionable

Company Calendar

Last Earnings
11/04/2021
Today
12/06/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/03/2022

Social Links


MarketRank

Overall MarketRank

2.25 out of 5 stars

Medical Sector

336th out of 1,390 stocks

Surgical & Medical Instruments Industry

35th out of 126 stocks

Analyst Opinion: 3.3Community Rank: 4.4Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.9 5 -4 -3 -2 -1 -












Anika Therapeutics (NASDAQ:ANIK) Frequently Asked Questions

Is Anika Therapeutics a buy right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Anika Therapeutics in the last twelve months. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Anika Therapeutics stock.
View analyst ratings for Anika Therapeutics
or view top-rated stocks.

How has Anika Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Anika Therapeutics' stock was trading at $36.39 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ANIK stock has increased by 7.9% and is now trading at $39.25.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Anika Therapeutics?

Anika Therapeutics saw a drop in short interest in November. As of November 15th, there was short interest totaling 756,300 shares, a drop of 29.3% from the October 31st total of 1,070,000 shares. Based on an average daily trading volume, of 72,200 shares, the short-interest ratio is currently 10.5 days. Approximately 5.3% of the company's stock are short sold.
View Anika Therapeutics' Short Interest
.

When is Anika Therapeutics' next earnings date?

Anika Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, March 3rd 2022.
View our earnings forecast for Anika Therapeutics
.

How were Anika Therapeutics' earnings last quarter?

Anika Therapeutics, Inc. (NASDAQ:ANIK) announced its quarterly earnings data on Thursday, November, 4th. The biotechnology company reported $0.05 earnings per share for the quarter, topping the consensus estimate of ($0.21) by $0.26. The biotechnology company had revenue of $39.54 million for the quarter, compared to analyst estimates of $36.45 million. Anika Therapeutics had a positive trailing twelve-month return on equity of 1.63% and a negative net margin of 3.96%. During the same period in the prior year, the firm earned ($0.45) earnings per share.
View Anika Therapeutics' earnings history
.

What guidance has Anika Therapeutics issued on next quarter's earnings?

Anika Therapeutics updated its FY 2021 earnings guidance on Thursday, December, 2nd. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $142.20 million-$144.81 million, compared to the consensus revenue estimate of $147.52 million.

What price target have analysts set for ANIK?

3 equities research analysts have issued 12-month target prices for Anika Therapeutics' stock. Their forecasts range from $46.00 to $55.00. On average, they expect Anika Therapeutics' stock price to reach $49.67 in the next year. This suggests a possible upside of 26.5% from the stock's current price.
View analysts' price targets for Anika Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Anika Therapeutics' key executives?

Anika Therapeutics' management team includes the following people:
  • Cheryl Renee Blanchard, President, Chief Executive Officer & Director
  • Michael L. Levitz, Chief Financial Officer, Treasurer & EVP (LinkedIn Profile)
  • Mira Leiwant, VP-Quality, Regulatory & Clinical Affairs
  • Steven W. Ek, Vice President-Research & Development
  • David Colleran, Secretary, Executive VP & General Counsel

What other stocks do shareholders of Anika Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Anika Therapeutics investors own include Alibaba Group (BABA), Broadcom (AVGO), Gilead Sciences (GILD), Micron Technology (MU), Skyworks Solutions (SWKS), Tesla (TSLA), Advanced Micro Devices (AMD), CVS Health (CVS), Enterprise Products Partners (EPD) and Ligand Pharmaceuticals (LGND).

What is Anika Therapeutics' stock symbol?

Anika Therapeutics trades on the NASDAQ under the ticker symbol "ANIK."

Who are Anika Therapeutics' major shareholders?

Anika Therapeutics' stock is owned by many different institutional and retail investors. Top institutional shareholders include BlackRock Inc. (16.03%), Kayne Anderson Rudnick Investment Management LLC (10.08%), Dimensional Fund Advisors LP (5.97%), Renaissance Technologies LLC (4.88%), Morgan Stanley (3.92%) and Janus Henderson Group PLC (3.21%). Company insiders that own Anika Therapeutics stock include James Loerop, John B Henneman III, Michael L Levitz, Michael L Levitz, Michael L Levitz and Raymond J Land.
View institutional ownership trends for Anika Therapeutics
.

Which institutional investors are selling Anika Therapeutics stock?

ANIK stock was sold by a variety of institutional investors in the last quarter, including Two Sigma Investments LP, BlackRock Inc., Two Sigma Advisers LP, Citadel Advisors LLC, Citigroup Inc., Russell Investments Group Ltd., GSA Capital Partners LLP, and Arrowstreet Capital Limited Partnership.
View insider buying and selling activity for Anika Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Anika Therapeutics stock?

ANIK stock was purchased by a variety of institutional investors in the last quarter, including Janus Henderson Group PLC, Trigran Investments Inc., Assenagon Asset Management S.A., Capital Management Corp VA, SG Americas Securities LLC, Jump Financial LLC, UBS Group AG, and Marshall Wace LLP. Company insiders that have bought Anika Therapeutics stock in the last two years include John B Henneman III, and Michael L Levitz.
View insider buying and selling activity for Anika Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Anika Therapeutics?

Shares of ANIK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Anika Therapeutics' stock price today?

One share of ANIK stock can currently be purchased for approximately $39.25.

How much money does Anika Therapeutics make?

Anika Therapeutics has a market capitalization of $566.65 million and generates $130.46 million in revenue each year. The biotechnology company earns $-23.98 million in net income (profit) each year or ($0.41) on an earnings per share basis.

How many employees does Anika Therapeutics have?

Anika Therapeutics employs 277 workers across the globe.

When was Anika Therapeutics founded?

Anika Therapeutics was founded in 1992.

What is Anika Therapeutics' official website?

The official website for Anika Therapeutics is www.anikatherapeutics.com.

Where are Anika Therapeutics' headquarters?

Anika Therapeutics is headquartered at 32 WIGGINS AVENUE, BEDFORD MA, 01730.

How can I contact Anika Therapeutics?

Anika Therapeutics' mailing address is 32 WIGGINS AVENUE, BEDFORD MA, 01730. The biotechnology company can be reached via phone at (781) 457-9000, via email at [email protected], or via fax at 781-305-9720.


This page was last updated on 12/6/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.